[DK] BioCapital Portefølje nyheder

Disse er udsendt af porteføljeselskaberne.
Henvendelser vedr. spørgsmål og kommentarer kan rettes til det enkelte selskab.

�鶹�� Emerge

16. marts 2022

SNIPR BIOME expands its Executive Management team and opens offices in the US and UK
�鶹�� Emerge

8. marts 2022

SNIPR BIOME announces opening of new BSL2/GMO2-classified laboratory in Copenhagen, Denmark
NMD Pharma

15. februar 2022

NMD Pharma Raises €35 Million in a new Financing
�鶹�� Emerge

25. januar 2022

SNIPR BIOME Announces U.S Food and Drug Administration grants Fast Track Designation for SNIPR001 for Prevention of Bloodstream Infections in Hematologic Cancer Patients
�鶹�� Emerge

11. januar 2022

SNIPR BIOME Announces FDA Clearance of Investigational New Drug (IND) Application for SNIPR001, a Novel CRISPR Therapy Targeting Life-Threatening E. coli Infections
�鶹�� Emerge

15. december 2021

SNIPR BIOME Announces Pioneering Work on CRISPR Targeting of Microbiomes is Recognised as European Patent Office Grants Fundamental Patent Rights
�鶹�� Emerge

10. december 2021

IO Biotech Announces Publication of Phase 1/2 Melanoma Clinical Trial Results in Nature Medicine
�鶹�� Emerge

10. november 2021

�鶹�� and Novo Holdings Portfolio Company IO Biotech Closes Initial Public Offering on the Nasdaq Global Market
Biotech

8. november 2021

Supporting research, talent and innovation
Talent og de innovative ideer i forskningsmiljøerne

8. november 2021

Hjælper forskning, talent og innovation på vej
�鶹�� Emerge

15. september 2021

IO Biotech Announces Clinical Collaboration with MSD to Evaluate IO102-IO103 with KEYTRUDA® (pembrolizumab) as First-Line Treatment in Metastatic Melanoma Patients in a Phase 3 Trial
�鶹�� Emerge

14. september 2021

MD Anderson and SNIPR BIOME collaborate to advance next-generation CRISPR microbiome therapeutics
�鶹�� Emerge

8. september 2021

AFYX Therapeutics Presents New Study Showing Therapeutic Antibody Delivery to Oral Mucosa Using Rivelin Biodegradable Mucoadhesive Patch
�鶹�� Emerge

8. juli 2021

IO Biotech Strengthens Leadership Team with Appointment of Keith Vendola as Chief Financial Officer
�鶹�� Emerge

1. juli 2021

NMD Pharma Doses the First Myasthenia Gravis Patient in a Combined Phase I/IIa Clinical Trial of NMD670
�鶹�� Emerge

25. juni 2021

Lundbeck Foundation strategy translates early-stage research into novel therapeutics
�鶹�� Emerge

25. juni 2021

�鶹��s strategi løfter den tidlige forskning til ny medicin
�鶹�� Emerge

27. maj 2021

CARB-X IS FUNDING SNIPR BIOME TO DEVELOP A CRISPR-ENGINEERED DRUG TO ERADICATE ESCHERICHIA COLI (E. COLI) BACTERIA IN CANCER PATIENTS TO PREVENT DEADLY INFECTIONS
�鶹�� Emerge

25. maj 2021

IO Biotech Strengthens Leadership Team with Appointment of Dr. Muhammad Al-Hajj as Chief Scientific Officer
�鶹�� Emerge

5. maj 2021

Cytoki Pharma raises $45million Series A financing
�鶹�� Emerge

11. marts 2021

Study Published in the European Journal of Oral Sciences Features AFYX Therapeutics’ Rivelin-CLO Patch for the Treatment of Oral Lichen Planus
�鶹�� Emerge

13. januar 2021

IO Biotech Completes Oversubscribed EUR 127 Million Series B Financing to Accelerate Clinical Programs in Oncology
�鶹�� Emerge

13. januar 2021

IO Biotech Completes Oversubscribed EUR 127 Million Series B Financing to Accelerate Clinical Programs in Oncology
�鶹�� Emerge

15. december 2020

The Food and Drug Administration (FDA) grants IO Biotech breakthrough therapy designation for IO102 and IO103 in combination with anti-PD-1 in unresectable/ metastatic melanoma
IO Biotech

15. december 2020

The Food and Drug Administration (FDA) grants IO Biotech breakthrough therapy designation for IO102 and IO103 in combination with anti-PD-1 in unresectable/ metastatic melanoma
AFYX Therapeutics

18. november 2020

AFYX Therapeutics Appoints Dennis Kim, M.D., MBA, as Chief Medical Officer
SNIPR BIOME

19. oktober 2020

SNIPR BIOME appoints Dr Milan Zdravkovic as Chief Medical Officer
NMD Pharma

6. oktober 2020

NMD Pharma Initiates a Combined Phase I/IIa Clinical Trial of NMD670 for the Treatment of Symptoms of Myasthenia Gravis
IO Biotech

18. september 2020

IO Biotech Announces Late-Breaking Oral Presentation of Phase 2 Clinical Melanoma Data Including Complete Response (CR) Rate of 45 Percent
NMD Pharma

14. juli 2020

NMD Pharma Receives Approval to Start a combined Phase I/IIa Clinical Trial of NMD670 for the Treatment of Symptoms of Myasthenia Gravis